

What is INVESTTools?

INVESTTools is a leading provider of independent investment advisory services and fundamental company research on the World Wide Web. With more than 50 nationally recognized publications and data sources on its Web site, INVESTTools provides active investors with a complete selection of brand-name online resources and the most flexible purchasing options available. INVESTTools was chosen by Barron's as one of the ten best web sites for investors.

Meet Jim Collins, Chairman, CEO and Principal of Insight Capital (over \$1 billion under management) and Editor of Biotech Insight

Jim Collins has seen a wide variety of markets during his 40 years of investment experience. He spent 25 years developing quantitative investment techniques at some of the most successful financial companies in the country. He holds an MBA from Harvard, a Bachelor's degree from Georgia Tech, is a Chartered Financial Analyst and a graduate of the Pacific Coast Banking School.

Welcome To Your FREE 30-Day Subscription!

This top-performing newsletter is yours **FREE** for 30 days, courtesy of INVESTTools. Just click the link below. Your satisfaction is guaranteed!

- **A Tomato That Can Treat Cancer?**
- **Painkillers made from Sea Snails and Tree Frogs?**
- **A Bona Fide End to World Hunger?**

New Advances In Biotechnology Are Creating Foods And Drugs To Cure Cancer, Battle Arthritis, End Starvation, Treat Blindness And More!



JIM COLLINS

Hi. I'm Jim Collins, editor of Biotech Insight

With the advent of new drugs and the understanding and exploitation of the human genome, Biotechnology will likely have the greatest impact on life over the next century. Just as the technology industry was the story of the 90's, biotech is likely to be the story of this decade.

With your FREE 30-Day trial to Biotech Insight, you'll get the inside story on the white-hot world of biotechnology, one of the most revolutionary and beneficial scientific advances of the last generation.

[Click Here For your FREE 30-Day Subscription to Biotech Insight](#)

The Biotech Industry is poised for fantastic growth!

The ancient Egyptians used biotechnology to bake leavened bread, ferment wine, and breed geese and cattle to meet their society's dietary needs. Today, scientists are using Biotechnology to create pest-resistant vegetables, pharmaceuticals to cure diseases like cancer, and foods to help end world hunger!

With approximately 4000 biotech companies operating around the world today, the biotechnology industry is growing rapidly. World markets in biotechnology-derived products are growing by an estimated 30% per annum, and was estimated at over \$140 billion in 2000. Worldwide, the biotech market is expected to reach \$1 trillion in the next few years.

And increasing numbers of these biotech companies are becoming profitable!

In the mid-1990's, the number of biotech companies with earnings could be counted on one hand. By 1999, 18 of 218 publicly-traded biotech companies had reached the black. It is estimated that 30 biotech companies will be profitable this year.

In every issue of Biotech Insight, you'll get in-depth reports and education about this exciting industry, and you'll learn firsthand about the companies, technologies and breakthrough products that will dominate the biotech sector.

You'll learn about:

What are Hulbert Financial Digest Performance Ratings?

Mark Hulbert started The Hulbert Financial Digest in 1979. Since then his periodic performance ratings of investment newsletters has helped individual investors by providing an independent, unbiased and consistent benchmark for evaluating which advisory services outperform their contemporaries.

Hulbert's rankings show which newsletters have performed the best, on both a total return and risk-adjusted basis, over specific periods of time.

Tax Deduction Reminder

Your subscription may be tax deductible as an investment expense under IRS Sections 67 and 212 to the extent that miscellaneous itemized deductions exceed 2% of your adjusted gross income. It is also fully tax deductible as a business expense by most corporations under Section 162 of the IRS Code.

Advances in life-improving prescription drugs.

The rapid aging of the population has increased demand for life-improving drugs. In 1990 there were 22 million American's aged 55 or older. By 2000, this figure increased to 59 million and is expected to reach 75 million by the end of this decade. In addition, American consumers spent nearly \$100 billion on prescription drugs in 2000, more than double what the nation spent in 1990.

In addition, The number of drugs in testing has exploded! There are more than 350 biotechnology drug products and vaccines currently in human clinical trials, and hundreds more in early development in the U.S. The number of patents issued annually to biotech companies has climbed from approximately 1500 in 1985 to over 9,000 in 1998. As a result, companies are now scrambling to get their products to market.

- One company has developed a breakthrough medication designed to support powerful cancer-fighting drugs and chemotherapy. This new drug helps ease discomfort and reduce the dangers of infection related to chemotherapy.
- A new generation of neuroscientists, trained in the young field of nerve growth and guidance, are using newly- discovered stem cells to repair spinal cord injuries and to treat cancer, heart disease and other disorders.
- Another company has unveiled a new weapon for the treatment of patients with metastatic breast cancer. In clinical studies, this drug slowed the growth of tumors and in some cases, made tumors disappear altogether
- Two new drugs have been developed from chemicals made by sea snails and tree frogs that hold the promise of stronger and broader action than morphine, with no tolerance.

If you missed out on last decade's millionaire-making opportunities in Semiconductors, PC's or the Internet, be warned: Today's investors who are loading up on the right biotech stocks may very well be tomorrow's "success story millionaires."

[Click Here For your FREE 30-Day Subscription to Biotech Insight](#)

New Discoveries in Disease-Fighting "Super Crops"

Malnutrition is reaching epidemic levels in the developing world. UN statistics show that 800 million people are chronically malnourished. By 2020, that number may top one billion. Millions of malnourished people, whose diets consist mostly of rice, have lost their sight due to Vitamin A deficiency, or are at risk from iron-deficiency anemia. Millions suffer from food allergies, heart disease and other nutrition-related ailments. Additionally, one in five infants is not vaccinated against diseases like diphtheria, tetanus and measles.

But what if these chronically malnourished people could get the recommended daily allowances of vitamin A and iron simply by eating their dietary staples like rice or corn? What if children could be vaccinated against deadly diseases like Hepatitis B just by eating a banana?

Biotechnology is allowing some of these ideas to become a reality!

Biotech foods could pack more nutritional content

A worldwide team of scientists has developed a strain of rice that contains increased levels of beta-carotene and iron, which can potentially prevent blindness, anemia and early death.

Biotech foods could deliver vaccines orally

Within a few years, the world may have access to edible vaccines! Imagine eating a banana that was genetically modified with a vaccine against Hepatitis B. Farmers in remote areas of the world could grow the vaccine-enhanced foods in their own communities, and administer it locally – eliminating the need for costly transportation or refrigeration of the vaccine.

Biotechnology could develop less allergenic, tastier or healthier crops

Advances in biotechnology may someday produce tomatoes with heightened levels of lycopene, a cancer-fighting agent. Or peanuts without pesky allergens. Even fruits and vegetables that resist destructive viruses without the use of pesticides.

Biotech foods can make it possible to grow more food on the same land, especially under tough growing conditions:

According to UN Food and Agriculture Organization officials, the recent mapping of the rice genome will help the international community achieve its goal of halving hunger by 2015. More importantly, the mapping of the rice genome could lead to improvements in similar cereals like wheat, barley and corn.

Biotechnology is one of the most revolutionary and beneficial scientific advances of the last generation! Don't get left behind as this industry steams ahead! Get the "lowdown" on biotech BEFORE it becomes "flavor of the month" on Wall Street!

[Click Here For your FREE 30-Day Subscription to Biotech Insight](#)

Biotech Insight: Sound Advice from the heart of the Biotech Industry:

With **Biotech Insight**, you'll get the same stockpicking and trend-identifying techniques that have made our flagship newsletter --**OTC Insight** -- one of the top-ranked newsletters for over 15 years! From our editorial offices based in San Diego, California – the heart of the Biotechnology Industry – Biotech Insight will give you the outlook, education, stock picks and strategies to put you on the leading edge of this innovative and profitable industry!

We combine three analytical techniques to select stocks and manage portfolios:

- First, our computers screen several thousand stocks on a regular basis to ensure that we miss nothing worth considering. We use proprietary quantitative screens to identify those stocks with the highest alphas and lowest standard deviation of return. We measure and evaluate risk, responsiveness, and volatility of stocks to find situations that match current (and future) market conditions. We believe in concentrating capital and finding the very best stocks. Our portfolios typically have no more than 10 to 15 stocks; sufficient diversification but not too much. As a result, a stock that is a big winner for us makes a real contribution to the portfolio! (remember: it takes only a few poorly performing stocks to significantly pull overall performance down, so if you own a mutual fund with 100 or more stocks, for example, you may not even notice the big winner because the effect is diluted.)
- The second analytical technique is good, old-fashioned fundamental analysis. We look for stocks with proven products and a strong pipeline. We typically don't buy penny stocks or unproven companies. In addition, we tend to shy away from companies with a history of management that lacks integrity.
- The third analytical step is performance analysis. This step judges the relative strength of a stock by ranking it from 1 to 99 with 99 meaning a stock has outperformed 99% of all other stocks for the last given time period. Since we're not "bottom pickers," we want stocks that have already proven themselves in the marketplace. To get the high returns we are looking for, it is very important that as many stocks as possible make a positive contribution to the returns.

The end result is our Buy List of the top 50 stocks listed in order of attractiveness for that month. Given all of the factors that go into picking the stocks, the highest ranked have the characteristics most likely to give us the returns we demand without undue risk.

With your FREE 30-Day subscription to Biotech Insight, you'll get our outlook on the most promising biotech sectors, highlights of various diseases and research, our 50-stock Biotech Buylist, live model portfolios and specific buy recommendations & in-depth reports on two promising Biotech companies each month.

Plus, enjoy these added INVESTools subscriber benefits:

- Weekly hotlines, with up-to-the-minute news, commentary and stock follow-ups!
- Immediate online delivery, and unlimited access to every issue
- Instant e-mail notices when each new issue is available
- Full text search and access to all back issues
- Convenient month-to-month billing
- No strings or hidden fees

Activate your FREE 30-Day subscription today and get two FREE REPORTS:

FREE REPORT # 1: Promising Biotech Sectors

- From Genomics to Pharmaceutical Drug Delivery, this list of Biotechnology's most promising sectors will give you insight on how companies in these sectors are striving to enhance the world we live in.

FREE REPORT #2: The Biotech Glossary: The "Layman's" Guide to Biotech Terms

- If you believe that doctors and scientists might as well as be talking a foreign language when they describe biotechnology, you're not alone. In fact many of the words are foreign in nature. This special glossary explains -- in plain English -- the terms and phrases associated with biotechnology.

GUARANTEED RISK-FREE SUBSCRIPTION!

Take a full 30 days to see if Biotech Insight is for you. You can cancel anytime during your trial and owe absolutely nothing.

But if you like what you're seeing—and enjoy being on the leading edge of this exciting industry—then do nothing! Your subscription will automatically continue at the low monthly rate of just \$24.95.

Plus, if you ever have any questions or concerns—you can always speak to a "real person" at the INVESTools Customer Service Center: 1-800-567-2683.

Put yourself on the leading edge of this innovative and profitable industry! Activate your FREE 30-Day subscription to Biotech Insight today!

Biotech Insight

Editor: Jim Collins and David Colville
Updated: Monthly
Subscription: \$24.95/Month
Category: Biotechnology Stocks

**Yes, I want to order a FREE trial Subscription
and see Jim Collins' recommendations immediately!**

It's quick, easy and FREE.

Already subscribed? [Click here!](#)

At INVESTools, your satisfaction is guaranteed.
If you have questions or concerns contact our [Customer Service Center](#).